Qian FH, Liu YX, Cao Y, Huang J, Zhu RH. Biomarker of severity in hospitalised patients with COVID-19: a retrospective study.
BMJ Open 2024;
14:e081627. [PMID:
39019644 PMCID:
PMC11256060 DOI:
10.1136/bmjopen-2023-081627]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/02/2023] [Accepted: 06/28/2024] [Indexed: 07/19/2024] Open
Abstract
BACKGROUND
The novel COVID-19 was rapidly spreading and was highly contagious. COVID-19 caused over 6 million deaths worldwide, with high mortality rates, particularly in severe cases.
OBJECTIVE
This study aimed to investigate whether serum albumin-neutrophil count to lymphocyte count ratio (NLR) score (ANS) could be used as a prognostic indicator of COVID-19 severity.
DESIGN
A retrospective study.
PARTICIPANTS
Based on the WHO diagnostic criteria, patients were classified as either non-severe (n=270) or severe (n=100).
PRIMARY AND SECONDARY OUTCOME MEASURES
NLR, serum albumin level and ANS.
MAIN RESULTS
The NLR of patients with severe disease was significantly higher than that of those with non-severe disease. Serum albumin levels were significantly lower in patients with severe disease than in those with non-severe disease. The cut-off values representing the maximum potential effectiveness of serum albumin and NLR were 33.5 g/L and 8.25, respectively, according to the Youden index. In patients with severe COVID-19, we observed that the serum albumin level, NLR and ANS were independent prognostic indicators of severe COVID-19 using logistic analysis. The relative risk of severe COVID-19 was 7.65 (95% CI 3.72 to 15.75, p<0.05) in the ANS 2 group compared with that in ANS 0.
CONCLUSIONS
ANS could be used as a prognostic indicator of COVID-19 severity.
Collapse